Vergelijking
Gonadorelin vs. Bremelanotide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
33515-09-2
189691-06-3
Molecuulmassa
1182.29 g/mol
1025.18 g/mol
Halfwaardetijd
0.1 h
2.7 h
Sequentie
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHWerkingsmechanisme
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
5
waarvan bij mensen
4
5
Geregistreerde effecten
4
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Gonadorelin and Bremelanotide?
- Gonadorelin is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or Bremelanotide?
- The highest available evidence level is "Humane studie" for Gonadorelin and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and Bremelanotide in Germany and the United States?
- Duitsland: Gonadorelin — Op recept, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Gonadorelin — Op recept, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.